In early tests, a vaccine served cut down the potential risk of relapse in people that use copyright. The vaccine activates your immune method to generate antibodies that connect to copyright and quit it from making its way into your brain. But we need much more analysis into whether the vaccine is safe and efficient about the long run.  Whatev